我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

促红细胞生成素治疗老年慢性心力衰竭的临床疗效及安全性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第2期
页码:
207-209
栏目:
临床研究
出版日期:
2014-01-20

文章信息/Info

Title:
Clinical study of therapeutic effects and safety of erythropoietin treatment for elderly patients with chronic heart failure
作者:
陈振云1陈 侃2熊海刚1刘祖秋1俞飞虎1晏 彪1
(1.解放军第113医院心内科,浙江 宁波 315040;2.第二军医大学附属长征医院心内科,上海 210003)
Author(s):
CHEN Zhen-yun1 CHEN Kan2 XIONG Hai-gang1 LIU Zu-qiu1 YU Fei-hu1 YAN Biao1
(1.Department of Cardiology, PLA 113th Hospital, Ningbo 315040, Zhejiang, China; 2.Department of Cardiovasology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China)
关键词:
促红细胞生成素心力衰竭慢性心功能分级
Keywords:
erythropoietin chronic heart failure heart function classification
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的:探讨促红细胞生成素(EPO)对老年慢性心力衰竭(CHF)患者的临床疗效、心功能分级、运动耐量影响及毒副作用。方法: 将80例CHF患者随机分成试药组(n=40)和对照组(n=40)。采用常规口服稳定剂量的利尿剂、地高辛、血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)、β受体阻滞剂等药物。试药组在对照组基础上皮下注射EPO 100 U/kg,每周1次,治疗6个月。结果: 试药组EPO治疗前后相比心功能测定LVEF、6分钟步行距离、心肌耗氧量峰值、血红蛋白均有显著改善(P<0.05),组间比较贫血组较非贫血组显著改善(P<0.05)。结论: EPO能改善CHF患者的心功能状态和临床症状,并提高运动耐量,且与贫血状态改善有关。
Abstract:
AIM:To study the effect and safety of erythropoietin (EPO) in the treatment of chronic heart failure (CHF) in elderly patients. METHODS: Eighty patients with CHF were randomly divided into two groups. Patients in the control group (n=40) were administered the routine treatment of CHF (diuretics, digoxin and ACEI), whereas in addition to the routine treatment, patients in the study group (n=40) were given a dose of EPO, 100 U/kg IH, once a week for 6 mouths. Left ventricular ejection fraction (LVEF) and hemoglobin (Hb) were measured, respectively, by echocardiography and laboratory examination. Heart function was examined by 6-min walking distance and NYHA heart function classification. RESULTS: Obvious improvements in LVEF, Hb, 6-min walking distance and NYHA heart function classification were observed in the study group after 6 months administration of EPO. The therapeutic effect was significantly different between groups (P<0.05). CONCLUSION: EPO treatment is safe and effective for improving heart function and enhances exercise tolerance in CHF patients.

参考文献/References

[1]张树风,戴启明.促红细胞生成素在心血管疾病中的作用研究进展[J].心血管病血进展,2012,3(33):407-410.
[2]庞 英,马建群.促红细胞生成素的心血管作用[J].心血管病血进展,2008,29(1):139-141.
[3]Mancini DM,Katzs D,Lang CC,et al.Effect of erythropoietin on exercise capaxity in patient with moderate to severe chronic heart failure[J].Circulation,2003,107(1):294-299.
[4]Ezekowitz JA McalisterFA,Amstrong PW.Anemia is Cocumon in heart failure and is associated with poor outcomes:insights from a cohort of 12 065 patients with new-onset heart failure[J]. Circulation,2003,107(2):223-225.
[5]van der Meer P,Voors AA,Lipsic E,et al.Erythropoietin in cardiovascular disease[J].Eur Heart J,2004,25(4):285-291.
[6]van der Meer P,Voors AA,Lipsic E,et al.Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure[J].J Am Coll Cardiol,2004,44(1):63-67.

备注/Memo

备注/Memo:
收稿日期:2013-06-27.
作者简介:陈振云,主任医师,硕士Email:CZY8lnk@163.com
更新日期/Last Update: 2014-01-16